Precigen Inc Market Cap ($2.38 Billion)
Market Cap & Net Worth: Precigen Inc (PGEN)
Precigen Inc market cap. Precigen Inc (NASDAQ:PGEN) has a market capitalization of $2.38 Billion ($2.38 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5439 globally and #1819 in its home market, demonstrating a 0.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Precigen Inc's stock price $6.64 by its total outstanding shares 358035247 (358.04 Million).
Precigen Inc Market Cap History (2015–2026)
Precigen Inc market cap history from 2015 to 2026. Data shows change from $10.79 Billion to $2.38 Billion (-13.70% CAGR). Check Precigen Inc (PGEN) stock price for real-time trading data and today's change.
Index Memberships
Precigen Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.09% | #145 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.01% | #625 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.13% | #91 of 263 |
Weight: Precigen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Precigen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Precigen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Precigen Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
154.54x
Precigen Inc's market cap is 154.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $8.70 Billion | $190.93 Million | -$186.61 Million | 45.57x | N/A |
| 2017 | $4.12 Billion | $230.98 Million | -$117.02 Million | 17.86x | N/A |
| 2018 | $2.34 Billion | $160.57 Million | -$509.34 Million | 14.58x | N/A |
| 2019 | $1.96 Billion | $31.99 Million | -$170.52 Million | 61.33x | N/A |
| 2020 | $3.65 Billion | $31.99 Million | -$170.52 Million | 114.15x | N/A |
| 2021 | $1.33 Billion | $14.27 Million | -$92.17 Million | 93.10x | N/A |
| 2022 | $544.21 Million | $26.91 Million | $28.32 Million | 20.22x | 19.22x |
| 2023 | $479.77 Million | $6.22 Million | -$95.90 Million | 77.07x | N/A |
| 2024 | $401.00 Million | $3.92 Million | -$126.23 Million | 102.17x | N/A |
| 2025 | $1.50 Billion | $9.68 Million | -$250.64 Million | 154.54x | N/A |
Competitor Companies of PGEN by Market Capitalization
Companies near Precigen Inc in the global market cap rankings as of October 31, 2026. See debt-free asset ratio of Precigen Inc to understand what proportion of total assets are financed by equity.
Key companies related to Precigen Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Precigen Inc (2015–2026)
Market capitalization of Precigen Inc from 2015 to today. Between 2015 and today, Precigen Inc's market cap moved from $10.79 Billion to $ 2.38 Billion, with a yearly change of -13.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.38 Billion | +58.85% |
| 2025 | $1.50 Billion | +273.21% |
| 2024 | $401.00 Million | -16.42% |
| 2023 | $479.77 Million | -11.84% |
| 2022 | $544.21 Million | -59.03% |
| 2021 | $1.33 Billion | -63.63% |
| 2020 | $3.65 Billion | +86.13% |
| 2019 | $1.96 Billion | -16.21% |
| 2018 | $2.34 Billion | -43.23% |
| 2017 | $4.12 Billion | -52.59% |
| 2016 | $8.70 Billion | -19.40% |
| 2015 | $10.79 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Precigen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.38 Billion USD |
| MoneyControl | $2.38 Billion USD |
| MarketWatch | $2.38 Billion USD |
| marketcap.company | $2.38 Billion USD |
| Reuters | $2.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more